Arrowhead Pharmaceuticals secured FDA approval for its RNAi therapy plozasiran (Redemplo) for familial chylomicronemia syndrome, marking the company’s transition to a commercial-stage biopharma. The approval positions Arrowhead head‑to‑head with Ionis, and Arrowhead immediately announced a markedly lower list price for its first product, signaling an aggressive commercial strategy. The approval validates RNAi platforms in rare lipid disorders and sets up a potential pricing and market-share battle between RNAi incumbents and antisense rivals as both seek uptake in a small but high‑value patient population.